前立腺肥大症治療薬の世界市場レポート 2025年

前立腺肥大症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.1％で55億8,000万米ドルに成長します。予測期間の成長は、新興国市場、新薬開発、認知度の向上と教育、規制当局の承認に起因します。予測期間の主な動向には、低侵襲治療、個別化医療、併用療法、患者中心のケア、遠隔医療とデジタルヘルス、研究開発などがあります。

この疾患は50歳以上の男性によく見られるため、世界の男性老年人口の増加は前立腺肥大症治療薬市場の主要な促進要因です。一例として、米国を拠点とする保健専門機関である世界保健機関（WHO）は2022年10月、2030年までに世界全体で推定6人に1人が60歳以上になると報告し、この数字は2050年までに21億人の高齢者に増加すると予測しています。米国国立衛生研究所（NIH）によると、前立腺肥大症（BPH）は51歳から60歳の男性の約50％が罹患しており、この割合は80歳以上の男性では90％にも達します。

前立腺肥大症治療薬（BPH）市場の成長は、前立腺疾患の有病率の増加によって牽引されると予想されます。前立腺疾患には、膀胱のすぐ下に位置する男性生殖器官である前立腺に影響を及ぼすさまざまな病状が含まれます。前立腺肥大症治療薬は、前立腺の状態に関連する排尿症状の管理と緩和において重要な役割を果たし、前立腺肥大の縮小と尿流の改善による救済を提供します。例えば、2024年6月、米国の政府機関である疾病管理予防センター（CDC）によると、2021年に米国で新たに報告された前立腺がんの症例数は23万6,659人で、2022年には3万3,363人の男性が前立腺がんで命を落としています。したがって、前立腺疾患の罹患率の上昇がBPH薬市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界前立腺肥大症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の前立腺肥大症治療薬市場：成長率分析
• 世界の前立腺肥大症治療薬市場の実績：規模と成長, 2019-2024
• 世界の前立腺肥大症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界前立腺肥大症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の前立腺肥大症治療薬市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アルファブロッカー
• 5α還元酵素阻害剤
• ホスホジエステラーゼ5阻害剤
• その他のタイプ
• 世界の前立腺肥大症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の前立腺肥大症治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他のエンドユーザー
• 世界の前立腺肥大症治療薬市場アルファ遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• タムスロシン
• アルフゾシン
• ドキサゾシン
• テラゾシン
• シロドシン
• 世界の前立腺肥大症治療薬市場5α還元酵素阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フィナステリド
• デュタステリド
• 世界の前立腺肥大症治療薬市場ホスホジエステラーゼ5阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• タダラフィル
• シルデナフィル
• 世界の前立腺肥大症治療薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗コリン薬
• ハーブサプリメント（ノコギリヤシ）
• 併用療法薬（アルファ遮断薬+5α還元酵素阻害剤）

第7章 地域別・国別分析

• 世界の前立腺肥大症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の前立腺肥大症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 前立腺肥大症治療薬市場：競合情勢
• 前立腺肥大症治療薬市場：企業プロファイル
  • Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Nymox Pharmaceutical Corporation
• AEterna Zentaris Inc.
• Pfizer Inc.
• IntelGenx Technologies Corp.
• Ipsen S.A.
• Novartis International AG
• Antibe Therapeutics Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Quest PharmaTech Inc.
• Bristol-Myers Squibb Company
• Endo Pharmaceuticals Inc.
• Kaken Pharmaceutical Co. Ltd.
• Impax Laboratories Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 前立腺肥大症治療薬市場2029：新たな機会を提供する国
• 前立腺肥大症治療薬市場2029：新たな機会を提供するセグメント
• 前立腺肥大症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Benign prostatic hypertrophy drugs are used to treat enlarged prostate glands by relaxing the muscles in the bladder neck and the muscle fibers in the prostate, thereby facilitating easier urination. Benign prostatic hypertrophy is a condition commonly observed in men over the age of 50.

The primary categories of drugs used for benign prostatic hypertrophy include alpha-blockers, 5-alpha reductase inhibitors, phosphodiesterase-5 inhibitors, and other medications. Alpha-blockers, also known as blockers or adrenoreceptor antagonists, are a type of pharmaceutical drug that functions by blocking adrenergic receptors. These drugs are used in various sectors, including hospital pharmacies, retail pharmacies, and others, and they are distributed through a range of channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The drugs for benign prostatic hypertrophy market research report is one of a series of new reports from The Business Research Company that provides drugs for benign prostatic hypertrophy market statistics, including drugs for benign prostatic hypertrophy industry global market size, regional shares, competitors with drugs for benign prostatic hypertrophy market share, detailed drugs for benign prostatic hypertrophy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for benign prostatic hypertrophy industry. This drugs for benign prostatic hypertrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drugs for benign prostatic hypertrophy market size has grown strongly in recent years. It will grow from $4.28 billion in 2024 to $4.58 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to aging population, increased awareness, advancements in drug therapies, healthcare access.

The drugs for benign prostatic hypertrophy market size is expected to see strong growth in the next few years. It will grow to $5.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to emerging markets, new drug developments, increasing awareness and education, regulatory approvals. Major trends in the forecast period include minimally invasive treatments, personalized medicine, combination therapies, patient-centered care, telemedicine and digital health, research and development.

The global growth in the male geriatric population is a key driver of the drugs for benign prostatic hypertrophy market since this condition is commonly observed in men aged 50 and above. As an example, in October 2022, the World Health Organization, a US-based specialized health agency, reported that by 2030, an estimated 1 in 6 individuals globally would be 60 years or older, and this figure is projected to increase to 2.1 billion elderly individuals by 2050. According to the National Institute of Health (NIH), Benign Prostatic Hyperplasia (BPH) affects approximately 50% of men aged between 51 and 60 years, and this percentage rises to as high as 90% among men aged over 80 years.

The growth of the drugs for benign prostatic hypertrophy (BPH) market is expected to be driven by the increasing prevalence of prostate diseases. Prostate diseases encompass a range of medical conditions affecting the prostate gland, a male reproductive organ located just below the bladder. Drugs for BPH play a crucial role in managing and alleviating urinary symptoms related to prostate conditions, offering relief by reducing prostate enlargement and improving urine flow. For instance, in June 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, there were 236,659 new cases of prostate cancer reported in the United States in 2021, with 33,363 men succumbing to the disease in 2022. Therefore, the rising incidence of prostate diseases is driving the growth of the BPH drug market.

Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on developing innovative products, such as Polish drugs, to effectively support patients with urological diseases. Polish drugs are pharmaceutical products developed to diagnose, treat, prevent, or alleviate symptoms of various diseases and conditions, regulated by relevant health authorities to ensure safety, efficacy, and quality. For instance, in June 2023, Adamed Sp. z o.o., a Poland-based pharmaceutical company, launched a combination drug containing solifenacin succinate and tamsulosin hydrochloride. This fixed-dose medication effectively addresses lower urinary tract symptoms (LUTS) associated with BPH by reducing bladder contractions through solifenacin and facilitating urination with tamsulosin. The combination improves patient outcomes when compared to tamsulosin monotherapy.

Major companies operating in the drugs for benign prostatic hypertrophy (BPH) market are focusing on technological advancements, such as developing new medications that address both enlarged prostate (BPH) and erectile dysfunction (ED), to gain a competitive edge. BPH refers to the non-cancerous enlargement of the prostate gland, while ED is the inability to achieve or maintain an erection sufficient for sexual activity. For instance, in September 2023, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical contract manufacturer, launched the Tamsulosin + Tadalafil Capsule, expanding its product offerings in the men's health sector. This innovative product, branded Cromax, combines Tamsulosin, which targets smooth muscle relaxation in the prostate and urethra to improve urine flow, with Tadalafil, which enhances blood flow to the penis to facilitate erections. This dual-action formulation provides a convenient treatment option for men suffering from both BPH and ED, while also demonstrating significant improvements in the International Prostate Symptom Score (IPSS).

Major companies operating in the drugs for benign prostatic hypertrophy market include Allergan Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Teva Pharmaceutical Industries Limited, Sanofi S.A., Nymox Pharmaceutical Corporation, AEterna Zentaris Inc., Pfizer Inc., IntelGenx Technologies Corp., Ipsen S.A., Novartis International AG, Antibe Therapeutics Inc., Bausch Health Companies Inc., Bayer AG, Quest PharmaTech Inc., Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Kaken Pharmaceutical Co. Ltd., Impax Laboratories Inc., GemVax & KAEL Inc., Merck & Co. Inc., Kissei Pharmaceutical Co. Ltd., Abbott Laboratories, Allium Medical Solutions Ltd., Asahi Kasei Corporation, Asclepion Laser Technologies GmbH, Boston Scientific Corporation, Biolitec AG, Coloplast A/S, Eli Lilly and Company, Endo International PLC, IPG Photonics Corporation, KARL STORZ SE & Co. KG, LISA Laser Products AG, Medifocus Inc., Olympus Corporation, Pharex Health Corporation, PNN Medical A/S, Quanta S.p.A.

North America was the largest region in the drugs for benign prostatic hypertrophy market in 2024. Middle East is expected to be the fastest-growing region in the drugs for benign prostatic hypertrophy market. The regions covered in the drugs for benign prostatic hypertrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the drugs for benign prostatic hypertrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The drugs for benign postratic hypertrophy market consists of sales of alfuzosin (Uroxatral), doxazosin (Cardura), tamsulosin (Flomax) and silodosin (Rapaflo). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drugs For Benign Prostatic hypertrophy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drugs for benign prostatic hypertrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drugs for benign prostatic hypertrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drugs for benign prostatic hypertrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Alpha Blocker; 5-alpha Reductase Inhibitor; Phosphodiesterase-5 Inhibitor; Other Types
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End User: Hospital Pharmacies; Retail Pharmacies; Other End-Users
• Subsegments:
• 1) By Alpha Blocker: Tamsulosin; Alfuzosin; Doxazosin; Terazosin; Silodosin
• 2) By 5-alpha Reductase Inhibitor: Finasteride; Dutasteride
• 3) By Phosphodiesterase-5 Inhibitor: Tadalafil; Sildenafil
• 4) By Other Types: Anticholinergics; Herbal Supplements (Saw Palmetto); Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)
• Companies Mentioned: Allergan Inc.; Astellas Pharma Inc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline plc; Teva Pharmaceutical Industries Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drugs For Benign Prostatic hypertrophy Market Characteristics

3. Drugs For Benign Prostatic hypertrophy Market Trends And Strategies

4. Drugs For Benign Prostatic hypertrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Drugs For Benign Prostatic hypertrophy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Drugs For Benign Prostatic hypertrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Drugs For Benign Prostatic hypertrophy Market Growth Rate Analysis
• 5.4. Global Drugs For Benign Prostatic hypertrophy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Drugs For Benign Prostatic hypertrophy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Drugs For Benign Prostatic hypertrophy Total Addressable Market (TAM)

6. Drugs For Benign Prostatic hypertrophy Market Segmentation

• 6.1. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alpha Blocker
• 5-alpha Reductase Inhibitor
• Phosphodiesterase-5 Inhibitor
• Other Types
• 6.2. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other End-Users
• 6.4. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Alpha Blocker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tamsulosin
• Alfuzosin
• Doxazosin
• Terazosin
• Silodosin
• 6.5. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of 5-alpha Reductase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Finasteride
• Dutasteride
• 6.6. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Phosphodiesterase-5 Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tadalafil
• Sildenafil
• 6.7. Global Drugs For Benign Prostatic hypertrophy Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anticholinergics
• Herbal Supplements (Saw Palmetto)
• Combination Therapy Drugs (Alpha Blocker + 5-alpha Reductase Inhibitor)

7. Drugs For Benign Prostatic hypertrophy Market Regional And Country Analysis

• 7.1. Global Drugs For Benign Prostatic hypertrophy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Drugs For Benign Prostatic hypertrophy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market

• 8.1. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drugs For Benign Prostatic hypertrophy Market

• 9.1. China Drugs For Benign Prostatic hypertrophy Market Overview
• 9.2. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drugs For Benign Prostatic hypertrophy Market

• 10.1. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drugs For Benign Prostatic hypertrophy Market

• 11.1. Japan Drugs For Benign Prostatic hypertrophy Market Overview
• 11.2. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drugs For Benign Prostatic hypertrophy Market

• 12.1. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drugs For Benign Prostatic hypertrophy Market

• 13.1. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drugs For Benign Prostatic hypertrophy Market

• 14.1. South Korea Drugs For Benign Prostatic hypertrophy Market Overview
• 14.2. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drugs For Benign Prostatic hypertrophy Market

• 15.1. Western Europe Drugs For Benign Prostatic hypertrophy Market Overview
• 15.2. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drugs For Benign Prostatic hypertrophy Market

• 16.1. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drugs For Benign Prostatic hypertrophy Market

• 17.1. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drugs For Benign Prostatic hypertrophy Market

• 18.1. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drugs For Benign Prostatic hypertrophy Market

• 19.1. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drugs For Benign Prostatic hypertrophy Market

• 20.1. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drugs For Benign Prostatic hypertrophy Market

• 21.1. Eastern Europe Drugs For Benign Prostatic hypertrophy Market Overview
• 21.2. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drugs For Benign Prostatic hypertrophy Market

• 22.1. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drugs For Benign Prostatic hypertrophy Market

• 23.1. North America Drugs For Benign Prostatic hypertrophy Market Overview
• 23.2. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drugs For Benign Prostatic hypertrophy Market

• 24.1. USA Drugs For Benign Prostatic hypertrophy Market Overview
• 24.2. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drugs For Benign Prostatic hypertrophy Market

• 25.1. Canada Drugs For Benign Prostatic hypertrophy Market Overview
• 25.2. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drugs For Benign Prostatic hypertrophy Market

• 26.1. South America Drugs For Benign Prostatic hypertrophy Market Overview
• 26.2. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drugs For Benign Prostatic hypertrophy Market

• 27.1. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drugs For Benign Prostatic hypertrophy Market

• 28.1. Middle East Drugs For Benign Prostatic hypertrophy Market Overview
• 28.2. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drugs For Benign Prostatic hypertrophy Market

• 29.1. Africa Drugs For Benign Prostatic hypertrophy Market Overview
• 29.2. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Drugs For Benign Prostatic hypertrophy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape And Company Profiles

• 30.1. Drugs For Benign Prostatic hypertrophy Market Competitive Landscape
• 30.2. Drugs For Benign Prostatic hypertrophy Market Company Profiles
  • 30.2.1. Allergan Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim International GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceutical Industries Limited Overview, Products and Services, Strategy and Financial Analysis

31. Drugs For Benign Prostatic hypertrophy Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Nymox Pharmaceutical Corporation
• 31.3. AEterna Zentaris Inc.
• 31.4. Pfizer Inc.
• 31.5. IntelGenx Technologies Corp.
• 31.6. Ipsen S.A.
• 31.7. Novartis International AG
• 31.8. Antibe Therapeutics Inc.
• 31.9. Bausch Health Companies Inc.
• 31.10. Bayer AG
• 31.11. Quest PharmaTech Inc.
• 31.12. Bristol-Myers Squibb Company
• 31.13. Endo Pharmaceuticals Inc.
• 31.14. Kaken Pharmaceutical Co. Ltd.
• 31.15. Impax Laboratories Inc.

32. Global Drugs For Benign Prostatic hypertrophy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drugs For Benign Prostatic hypertrophy Market

34. Recent Developments In The Drugs For Benign Prostatic hypertrophy Market

35. Drugs For Benign Prostatic hypertrophy Market High Potential Countries, Segments and Strategies

• 35.1 Drugs For Benign Prostatic hypertrophy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Drugs For Benign Prostatic hypertrophy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Drugs For Benign Prostatic hypertrophy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer